4.7 Review

Neurology of inherited glycosylation disorders

期刊

LANCET NEUROLOGY
卷 11, 期 5, 页码 453-466

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(12)70040-6

关键词

-

资金

  1. Rocket Fund
  2. National Institutes of Health [R01DK55615]
  3. Sanford Professorship
  4. Avtal om lakarutbildning och forskning
  5. Crafoordska stiftelsen
  6. NINDS [U54 NS065768]
  7. National MS Society
  8. Actelion Pharmaceuticals
  9. Merck-Serono

向作者/读者索取更多资源

Congenital disorders of glycosylation comprise most of the nearly 70 genetic disorders known to be caused by impaired synthesis of glycoconjugates. The effects are expressed in most organ systems, and most involve the nervous system. Typical manifestations include structural abnormalities (eg, rapidly progressive cerebellar atrophy), myopathies (including congenital muscular dystrophies and limb-girdle dystrophies), strokes and stroke-like episodes, epileptic seizures, developmental delay, and demyelinating neuropathy. Patients can also have neurological symptoms associated with coagulopathies, immune dysfunction with or without infections, and cardiac, renal, or hepatic failure, which are common features of glycosylation disorders. The diagnosis of congenital disorder of glycosylation should be considered for any patient with multisystem disease and in those with more specific phenotypic features. Measurement of concentrations of selected glycoconjugates can be used to screen for many of these disorders, and molecular diagnosis is becoming more widely available in clinical practice. Disease-modifying treatments are available for only a few disorders, but all affected individuals benefit from early diagnosis and aggressive management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据